Re: Competitors in TCR-T -- Iova, Intellia, TCRR and Timmunity
>> so since it has not already been activated, then it can be used to create the synthetic lymphocyte by gene editing, <<
Aw shucks, dnmun. I thought the metaphor that naive Tcells had not yet been programmed for their mission was a decent simplification. I'm glad you are around to square me away.
I left a question to you in #25154. Do you think that any firm has yet mastered (proven the concept in trials) in Treg control that opens the door to allogeneic from a single host and, as well, creates a market for organ transplants that do not require a close MHC match from a donor? In my view, many including Sangamo, are "working on it" but until the black boxes in CAR-T are removed, I think the challenge is not yet overcome.
Said in another way, do you know of anyone using single-host allo (approved) that does not having a black box? Thanks in advance.